HMN 2025: What is the key mechanism driving neuroblastoma growth

A model new study led by Children’s Hospital Los Angeles has found a novel mechanism behind neuroblastoma growth: the shape and building of the extracellular matrix.

The study, led by JinSeok Park, Ph.D., and published in Advanced Materials, is the first to point {{that a}} fibrous extracellular matrix building—the group of proteins surrounding and supporting tumors—triggers neuroblastoma cells to become further aggressive and proof in opposition to remedy.

In addition, the group developed an trendy, first-of-its-kind nanoscale model to overview this phenomenon.

“Our findings shed new light on the necessary operate of the extracellular matrix in neuroblastoma,” says Dr. Park, an investigator throughout the Cancer and Blood Disease Institute at CHLA—a world chief in neuroblastoma care and evaluation and crucial pediatric cancer program throughout the Western U.S. “This opens up a model new resolution to look at and possibly take care of high-risk kinds of this childhood cancer.”

Why do cells become further aggressive?

The second-most frequent robust tumor in children (after thoughts tumors), neuroblastoma arises from immature nerve cells and often impacts children between the ages of two and 4. Nearly half of victims are recognized with high-risk, metastatic sickness, which has a 50% mortality charge.

Neuroblastoma cells have two important types: adrenergic, which resemble nerve cells, and mesenchymal, which behave further like stem cells and tend to unfold further merely.

Prior evaluation has found that adrenergic cells can transition into mesenchymal cells, which may be why some victims reply poorly to remedy.

Dr. Park and his group investigated how and why this transition takes place, notably making an attempt on the bodily building of the extracellular matrix—an understudied aspect of the tumor microenvironment.

Key findings

To do this, the group created a selected lab model with tiny, nanoscale grooves that match the scale and type of the actual extracellular matrix. Researchers then coated the ground with collagen III, a protein which varieties the extraordinarily aligned fibers throughout the matrix. This novel model allowed the group to further intently study how the matrix works.

The researchers found that:

• High-risk and relapsed neuroblastoma tumors have an extracellular matrix or “scaffolding” with further aligned and structured fibers than low-risk tumors.
• The stiffer, further fibrous scaffolding exerts bodily stress on the tumor cells, triggering them to shift from adrenergic into mesenchymal.
• This shift occurs by the use of two signaling pathways—rho-kinase (ROCK) and yes-associated protein (YAP). The fibrous building first prompts ROCK. ROCK then prompts YAP, which turns off adrenergic-related genes and pushes cells to rework into the additional aggressive type.

Importantly, when the group blocked the ROCK pathway, it stopped this transition from occurring.

“We’ve confirmed for the first time {{that a}} biophysical problem—the shape and building of the extracellular matrix—is driving this alteration and may play a major operate in worsening neuroblastoma outcomes,” says Dr. Park.

Dr. Park’s lab is now using its new model to larger understand the mechanisms inflicting these tumors to be proof in opposition to current therapies. The group may be exploring exactly what causes the extracellular matrix to become so fibrous throughout the first place.

What this means for victims

One promising aspect of the group’s discoveries is that remedy that block the ROCK pathway are already FDA-approved for various circumstances and have been confirmed to gradual tumor progress. In addition, an FDA-approved drug known as verteporfin is known to dam YAP carry out.

“More study is required, nonetheless our findings counsel that inhibiting YAP is also a novel therapeutic approach which may suppress the transition to further aggressive sickness,” Dr. Park says. “This is an thrilling step in direction of bettering outcomes for teenagers with high-risk neuroblastoma.”